FindTrial
Sign In

A study to determine the optimum timing of Hepatitis B vaccination during treatment of Acute Lymphoblastic leukemia( a type of blood cancer)

â??Comparison of Efficacy of Hepatitis B Vaccination during Induction with Maintenance Phase of Chemotherapy in Acute Lymphoblastic Leukemia.â??

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009402
Enrollment
60
Registered
2017-08-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- acute lymphoblastic leukemia Health Condition 2: C910- Acute lymphoblastic leukemia [ALL] Health Condition 3: C910- Acute lymphoblastic leukemia [ALL]

Interventions

Intervention1: Group I: Group I will receive vaccination in induction phase of chemotherapy. Double the standard dose of recombinant hepatitis B vaccine that is 20 mcg in subjects less than 10 years o

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Newly diagnosed acute lymphoblastic leukemia patients attending JIPMER medicine/ medical oncology OPD 2) Receiving chemotherapy (in either induction phase or Maintenance phase) 3) Seronegative for HBsAg 4) Anti HBs 5) Normal liver function test

Exclusion criteria

Exclusion criteria: 1) Patients already having Hepatitis B infection 2) Patients with immunocompromised state due to any other reason (e.g. HIV)

Design outcomes

Primary

MeasureTime frame
anti HBS titreTimepoint: 1 month after completing vaccination—

Secondary

MeasureTime frame
new HBsAg positivityTimepoint: 1,2,3 months after starting vaccination—

Countries

India

Contacts

Public ContactDr Gopisree Peringeth

JIPMER

rpsmed@gmail.com9500941171

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 22, 2026